Cargando…

RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer

Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKI), including gefitinib, provide a significant clinical benefit in non-small-cell lung cancer (NSCLC) patients, the acquisition of drug resistance has been known to limit the efficacy of EGFR-TKI therapy. In this stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaneto, Naoki, Yokoyama, Satoru, Hayakawa, Yoshihiro, Kato, Shinichiro, Sakurai, Hiroaki, Saiki, Ikuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317907/ https://www.ncbi.nlm.nih.gov/pubmed/24750242 http://dx.doi.org/10.1111/cas.12425

Ejemplares similares

P38 pathway as a key downstream signal of connective tissue growth factor to regulate metastatic potential in non‐small‐cell lung cancer
por: Kato, Shinichiro, et al.
Publicado: (2016)

Mesenchymal-transitioned cancer cells instigate the invasion of epithelial cancer cells through secretion of WNT3 and WNT5B
por: Kato, Shinichiro, et al.
Publicado: (2014)

COP9 signalosome subunit 5 regulates cancer metastasis by deubiquitinating SNAIL
por: Watanabe, Kensuke, et al.
Publicado: (2018)

Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2
por: Zhou, Yue, et al.
Publicado: (2015)

Multi-Pathway Cellular Analysis on Crude Natural Drugs/Herbs from Japanese Kampo Formulations
por: Eshima, Shizuka, et al.
Publicado: (2015)

AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells
por: Abdelhamed, Sherif, et al.
Publicado: (2016)

miR-135a Confers Resistance to Gefitinib in Non-Small Cell Lung Cancer Cells by Upregulation of RAC1
por: Zhang, Tingting, et al.
Publicado: (2018)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2013)

Berberine enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast cancer
por: REFAAT, ALAA, et al.
Publicado: (2013)

Effect of Keishibukuryogan on Genetic and Dietary Obesity Models
por: Gao, Fengying, et al.
Publicado: (2015)

Selective inhibition of TNF-α-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib
por: Ueno, Y, et al.
Publicado: (2005)

ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells
por: Qi, Mengfan, et al.
Publicado: (2018)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
por: Shimomura, Iwao, et al.
Publicado: (2013)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Targeting PSMD14 inhibits melanoma growth through SMAD3 stabilization
por: Yokoyama, Satoru, et al.
Publicado: (2020)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer
por: Sun, Cuilan, et al.
Publicado: (2020)

Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells
por: Li, Jiajin, et al.
Publicado: (2016)

Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2014)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer
por: Lu, Xiangdong, et al.
Publicado: (2021)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

Anti-Proliferative Effect of Cytohesin Inhibition in Gefitinib-Resistant Lung Cancer Cells
por: Bill, Anke, et al.
Publicado: (2012)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells
por: Pan, Zhenzhen, et al.
Publicado: (2020)

Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
por: Park, Soo-Yeon, et al.
Publicado: (2010)

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells
por: Zhang, Yi, et al.
Publicado: (2015)

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer
por: Sin, Thomas K., et al.
Publicado: (2016)

Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer
por: Liu, Shuliang, et al.
Publicado: (2016)

Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
por: Yeung, Yiu To, et al.
Publicado: (2018)

Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer
por: Li, Bin, et al.
Publicado: (2016)

Delivery of gefitinib with an immunostimulatory nanocarrier improves therapeutic efficacy in lung cancer
por: Diao, Dingwei, et al.
Publicado: (2021)

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
por: Miyagi, Michihito, et al.
Publicado: (2022)

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer: HMGB1-mediated autophagy promotes gefitinib resistance
por: Lei, Tianyao, et al.
Publicado: (2022)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro
por: Hu, Yong, et al.
Publicado: (2017)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2013)

The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India
por: Mehta, Asmita Anilkumar, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e7sdh4rdm88ql0vh3e5qe8vslu